<DOC>
	<DOCNO>NCT00897104</DOCNO>
	<brief_summary>A study compare rizatriptan ( MK0462 ) 5 mg mouth ( p.o . ) sumatriptan 50 mg p.o . acute treatment migraine attack .</brief_summary>
	<brief_title>MK0462 5 mg , Sumatriptan 50 mg , Placebo Comparison Study ( 0462-029 )</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>Participant least 6month history migraine , without aura Participant male , female , must postmenopausal , surgically sterilize , take adequate contraceptive precaution Participant judge good health , apart migraine Participant Pregnant nursing mother Participant history current evidence drug alcohol abuse Participant history clinical evidence cardiovascular disease Participant clinically significant Electrocardiography ( ECG ) abnormality Participant rest systolic blood pressure great 145 mm Hg diastolic le 95 mm Hg screening Participant receive treatment investigational device compound within 30 day study Participant typically suffer less 1 8 attack migraine per month Participant difficulty distinguish his/her migraine attack tension interval headache Participant currently take monoamine oxidase inhibitor , methysergide lithium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>